Journal of Pharmaceutical Sciences & Emerging DrugsISSN: 2380-9477

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Editorial, J Pharm Sci Emerg Drugs Vol: 5 Issue: 1

Synthesis, Pharmacokinetics, Pharmacodynamics, Dosing, Stability, Safety and Efficacy of Orphan Nano Drugs to Treat High Cholesterol and Related Conditions and to Prevent Cardiovascular Disease Under Synchrotron Radiation

Alireza Heidari*

Faculty of Chemistry, California South University, 14731 Comet St. Irvine, CA 92604, USA

*Corresponding Author : Alireza Heidari
Faculty of Chemistry, California South University, 14731 Comet St. Irvine, CA 92604, USA
E-mail: Scholar.Researcher.Scientist@gmail.com

Received: May 29, 2017 Accepted: June 03, 2017 Published: June 09, 2017

Citation: Heidari A (2017) Synthesis, Pharmacokinetics, Pharmacodynamics, Dosing, Stability, Safety and Efficacy of Orphan Nano Drugs to Treat High Cholesterol and Related Conditions and to Prevent Cardiovascular Disease Under Synchrotron Radiation. J Pharm Sci Emerg Drugs 5:1. doi:10.4172/2380-9477.1000e104

Abstract

Orphan Nano drugs such as Rituxan, Revlimid, Soliris, Afinitor, Tasigna, Velcade, Avonex, Alimta, Yervoy, Sprycel, Rebif, Kalydeco, Jakavi, Sutent, Kyprolis, Kogenate, NovoSeven, Nexavar, Copaxone, Ibrutinib and their derivatives are versatile intermediates in the field of pharmaceuticals, cosmetics and perfumes. Further, Rituxan, Revlimid, Soliris, Afinitor, Tasigna, Velcade, Avonex, Alimta, Yervoy, Sprycel, Rebif, Kalydeco, Jakavi, Sutent, Kyprolis, Kogenate, NovoSeven, Nexavar, Copaxone, Ibrutinib and their derivatives are important derivatives of Orphan Nano drugs, which have received considerable attention in recent years because of their wide range of biological and pharmaceutical activities. Several methods have been reported for the synthesis, pharmacokinetics, pharmacodynamics, dosing, stability, safety and efficacy of these Nano compounds in literature. However, most of these methods use solvents which make the workup procedure complicated or use expensive catalysts and high temperatures. Following our continued interests in the synthesis, pharmacokinetics, pharmacodynamics, dosing, stability, safety and efficacy of heterocyclic Nano compounds, we studied the synthesis, pharmacokinetics, pharmacodynamics, dosing, stability, safety and efficacy of Orphan Nano drugs to treat high cholesterol and related conditions and to prevent cardiovascular disease under synchrotron radiation using a one– pot three component reaction under solvent free condition and a new base catalyst. The reaction gave the desired products in low reaction time and excellent yields.

Keywords: Cefotaxime; Infrared spectroscopy; Quality control; Validation; Quantification; Green chemistry

Download PDF

Introduction

Orphan Nano drugs such as Rituxan, Revlimid, Soliris, Afinitor, Tasigna, Velcade, Avonex, Alimta, Yervoy, Sprycel, Rebif, Kalydeco, Jakavi, Sutent, Kyprolis, Kogenate, NovoSeven, Nexavar, Copaxone, Ibrutinib and their derivatives are versatile intermediates in the field of pharmaceuticals, cosmetics and perfumes. Further, Rituxan, Revlimid, Soliris, Afinitor, Tasigna, Velcade, Avonex, Alimta, Yervoy, Sprycel, Rebif, Kalydeco, Jakavi, Sutent, Kyprolis, Kogenate, NovoSeven, Nexavar, Copaxone, Ibrutinib and their derivatives are important derivatives of Orphan Nano drugs, which have received considerable attention in recent years because of their wide range of biological and pharmaceutical activities [1-16]. Several methods have been reported for the synthesis, pharmacokinetics, pharmacodynamics, dosing, stability, safety and efficacy of these Nano compounds in literature [17-37]. However, most of these methods use solvents which make the workup procedure complicated or use expensive catalysts and high temperatures. Following our continued interests in the synthesis, pharmacokinetics, pharmacodynamics, dosing, stability, safety and efficacy of heterocyclic Nano compounds, we studied the synthesis, pharmacokinetics, pharmacodynamics, dosing, stability, safety and efficacy of Orphan Nano drugs to treat high cholesterol and related conditions and to prevent cardiovascular disease under synchrotron radiation using a one– pot three component reaction under solvent free condition and a new base catalyst. The reaction gave the desired products in low reaction time and excellent yields.

On the other hand, Orphan Nano drugs constitute a major class of naturally occurring Nano compounds and interest in their chemistry and pharmacology continues unabated because of their usefulness as biologically and pharmaceutically active agents. There has been considerable interest in Orphan Nano drugs and their derivatives, not least because of their value for a variety of industrial, biological, medical, medicinal, clinical, pharmaceutical and chemical synthetic uses. As a result, a large number of methods have appeared describing novel synthesis, pharmacokinetics, pharmacodynamics, dosing, stability, safety and efficacy of these Orphan Nano drugs have been of interest because of their biological and pharmaceutical activities and a few methods have been reported for their synthesis, pharmacokinetics, pharmacodynamics, dosing, stability, safety and efficacy.

However, development of more environmentally friendly synthetic process is a rising interest in the industrial, biological, medical, medicinal, clinical, pharmaceutical, physical and chemical communities. In addition to Orphan Nano drugs derivatives such as Rituxan, Revlimid, Soliris, Afinitor, Tasigna, Velcade, Avonex, Alimta, Yervoy, Sprycel, Rebif, Kalydeco, Jakavi, Sutent, Kyprolis, Kogenate, NovoSeven, Nexavar, Copaxone, Ibrutinib abundance and for industrial, biological, medical, medicinal, clinical, pharmaceutical, physical, chemical and safety reasons, Orphan Nano drugs as biological, medical, medicinal, clinical, pharmaceutical, physical and chemical agents have naturally become an alternative as an environmentally benign solvent. Moreover, it has been found that reactions under synchrotron radiation using a one–pot three component reaction under solvent free condition and a new base catalyst can facilitate access to different reactivity and selectivity patterns compared with those observed in common organic solvents due to its unique industrial, biological, medical, medicinal, clinical, pharmaceutical, physical and chemical properties to treat high cholesterol and related conditions and to prevent cardiovascular disease, cystic fibrosis, homozygous familial hypercholesterolemia and Wilson’s disease and so on under synchrotron radiation.

References

international publisher, scitechnol, subscription journals, subscription, international, publisher, science

Track Your Manuscript

Explore SciTechnol

Awards Nomination

Google Scholar citation report

Citations : 356

Journal of Pharmaceutical Sciences & Emerging Drugs received 356 citations as per Google Scholar report

Citation image

Journal Highlights